Sulfonylureas in type 2 diabetes mellitus: current evidence, conflicts and clinical implications by Chiedozie, Kenneth Ugwoke et al.
100
ABSTRACT
ype 2 diabetes mellitus (T2DM) is a chronic 
metabol ic  disorder  character ized by 
hyperglycemia, insulin insensitivity, declining T
insulin production, and eventual pancreatic β-cell 
(1)
failure . The disease prevalence has been increasing 
steadily over the past 30 years, rapidly approaching 
epidemic proportions in many countries across the 
world. It is predicted that the prevalence of T2DM in 
adults will rise futher in the next two decades and 
much of the increase will occur in developing countries 
where the majority of patients are aged between 45 and 
(2)
64 years . Studies examining data trends within Africa 
point to evidence of a dramatic increase in prevalence 
in both rural and urban settings, affecting both gender 
(3)
equally .
Although the pathogenesis  and long-term 
complications of T2DM are fairly well known, its 
prevention and treatment remain challenging, with 
only half of the patients achieving the recommended 
(4)
level of glycated haemoglobin (HbA1c) . Studies have 
shown that there was significant reduction in the 
incidence of T2DM with a combination of maintaining 
healthy body mass index, high fibre – low saturated 
and trans-fats diet, regular exercise, abstinence from 
smoking and moderate consumption of alcohol, 
suggesting that majority of T2DM can be prevented by 
(5-8)
lifestyle modification .
No cure has yet been found for the disease; however, 
treatment options in addition to lifestyle modifications 
include various classes of oral glucose lowering agents.  
Since the commercial introduction of sulfonylureas in 
1956, till 1995, sulfonylureas and metformin were the 
only oral glucose lowering agents. From 1995 all of the 
other oral glucose lowering agents were introduced: α-
g l u c o s i d a s e  i n h i b i t o r s  ( A G - i )  i n  1 9 9 5 ,  
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INTRODUCTION: We sought to explore the current state of evidence on sulfonylurea therapy in type 2 
diabetes mellitus (T2DM) and critically examine the recommendations of major practice guidelines, and the overall 
ramifications of the issues thereof in current clinical practice.
METHOD: We searched PUBMED, MEDLINE and other databases, and selected, analysed and interpreted 
relevant original studies, reports and reviews on the subject.
RESULTS: A compelling body of literature exist on the sulfonylurea use in T2DM, with a remarkable number of 
studies illuminating substantial clinical issues associated with their use. Nevertheless, definitive evidence is still 
limited in terms of unequivocally clarifying some of the concerns. All major practice guidelines mirrored a historical 
trend of consistent endorsement of sulfonylureas as first or second line agents in T2DM management. However, 
based on re-evaluation of available evidence, some latest guidelines have reflected a significantly declined 
confidence in the traditional status accorded to sulfonylureas in T2DM management, conspicuously contrasting 
other existing guidelines.
CONCLUSION: The apparent inconsistencies and deficiencies in the available body of evidence and the 
conflicting recommendations in current guidelines have raised new questions and complicated clinical 
considerations, creating a novel dilemma in the clinical use of sulfonylureas. 
KEYWORDS:  Sulfonylurea; type 2 diabetes mellitus; evidence; guidelines; clinical practice.
Review Article 
Nigerian Journal of Medicine, Vol. 26 No. 1, January - March, 2017, ISSN 1115-2613
NigerJMed2017: 68-75 
” 2017. Nigerian Journal of Medicine
68
that sulfonylurea treatment may also inhibit 
glycogenolysis and gluconeogenesis and stimulate 
g l y c o g e n e s i s  a n d  g l y c o l i t i c  p a t h w a y  b y  
regulatingthephosphofructokinase-2/ fructose2,6-
b isphosphatase  and phosphoenolpyruvate  
(14,15)
carboxykinase . Sulfonylureas appear to reduce 
glucagon and free fatty acid concentration in the 
plasma, which may further contribute to the insulin 
(14)
sensitivity . Some agents in the class also increase 
glucose uptake in the muscles, not only by increasing 
GLUT4 and GLUT1 expression but also by stimulating 
(16,17)
glycogenesis and lipogenesis .
The principal site of sulfonlyurea metabolism is the 
liver. There it is extensively metabolised primarily by 
the cytochrome P450 2C9 isoencyme, which gives rise 
to a relatively short half-life of most sulfonylureas (up 
to 10 hours), except for chlorpropramide, which has a 
(18)
half life of 24-48 hours . In terms of efficacy, on 
(19)
average, sulfonylureas lower HbA1c by 1-2% . 
Complications and adverse effects associated with 
sulfonylureas
Despite its strong antidiabetic action, several adverse 
effects of sulfonylureas are reported. The most 
common and worrisome adverse effect  of  
sulfonylureas, more likely to occur with the longer 
(20)
acting agents (Table 1), is hypoglycaemia .β-cells in 
the pancreatic islet are constitutively stimulated by 
sulfonylurea to secrete insulin regardless of the plasma 
glucose level, leading to hypoglycaemia due to 
excessive insulin production. In the case of patients 
with diabetes older than 60 years of age, 
hypoglycaemia is ranked as the second most common 
(21)
non-fatal complication . Hypoglycaemic events 
frequently cause sudden loss of consciousness, which is 
followed by traumatic injuries upon falling. A 
significant relationship exists between hypoglycaemia 
(22)
and fall-related fractures in older patients . Thus, 
sulfonylureas should be used with caution in patients 
with irregular eating habits, alcoholics, those on β-
blocker therapy and elderly patients. 
Another important problem associated with 
sulfonylureas is an increased risk of mortality and 
cardiovascular events compared to other antidiabetic 
agents. This relationship is investigated in a number of 
existing studies. For example, the all-cause mortality 
for metformin-monotherapy was revealed to be 
significantly lower than that for sulfonylurea-
(23)
monotherapy in T2DM patients . Similarly, when 
glycaemic control with metformin failed, DPP-
4i(linagliptin) caused fewer cardiovascular events than 
(24)
sulfonylurea as a second-line treatment . The 
association with adverse cardiovascular effects is 
thiazolidinediones (TZD) in 1996, meglitinides (GLN) 
in 1997, GLP-1 receptor agonists (GLP1-RA) in 2005, 
amylin agonists in 2005, DPP-4 inhibitors (DPP-4i) in 
2006, colesevelam approved for T2DM in 2008, quick-
release bromocriptine approved for T2DM in 2009 and 
(9)
SGLT-2 inhibitors (SGLT-2i) in 2013 . As pointed out 
above, sulfonylureas have been a cornerstone of T2DM 
pharmacotherapy for over 50 years; however, their 
status in T2DM management has become a recent focus 
of interest due to apparent inconsistencies in evidence 
and contrasting recommendations among current 
guidelines. 
Pharmacology of sulfonylureas
While the sulfonylureas represent a rational and 
effective class of  antihyperglycemic agents, 
inter individual  var iabi l i ty  exis ts  in  their  
pharmacodynamics, pharmacokinetics and adverse 
effects. In order to elucidate the genetic underpinnings 
of this response variability, many studies have sought 
to determine the influence of drug-metabolizing 
e n z y m e  p o l y m o r p h i s m  o n  s u l f o n y l u r e a  
pharmacokinetics. In addition, polymorphisms in 
sulfonylurea target genes and diabetes genes have 
recently been recognised as important determinants of 
sul fonylurea pharmacodynamics  in  T2DM     
(10-12)
patients . 
The evolution of sulfonylureas resulted in what is 
currently referred to as the different generations of 
agents (Table 1). They all have the same mechanism of 
action; however the second generation of sulfonylureas 
(12)
have higher potency than the first-generation agents . 
Sulfonylureas stimulate insulin release by binding to 
ATP-sensitive potassium channels on the surface of 
pancreatic β-cells. Structurally, K+ATP-channels  are  
hetero-octameric  protein  complex  composed  of 
inward-rectifying potassium channels  (Kir6.2)  and  
sulfonylurea  receptor  (SUR1)  with  a stoichiometry  
of  4:4, which make up one KATP-channel complex 
(12)
(Figure 1) . Binding of sulfonylurea to SUR1 results in 
closure of the K+-ion channel, which leads to increased 
c o n c e n t r a t i o n  o f  i n t r a c e l u l a r  p o t a s s i u m ,  
depolarization of β-cell mambrane, and the subsequent 
opening of voltage-gated calcium channels. Influx of 
calcium stimulates the glucose-independent exocytosis 
of insulin-containing secretory granules into the 
(13)
circulation . As insulin secretagogues, sulfonylureas 
are dependent on functioning β-cells and are therefore 
usually used early in the course of the disease process. 
Later in the progress of T2DM, efficacy of sulfonylureas 
may decline with increasing dysfunction of β-cells, and 
a need for a dosage increase or a switch to other therapy 
(12)
may be necessary .
Both in vivo and in vitro studies have demonstrated 
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classes of antihyperglycemic agents in the 
pharmacotherapy of T2DM. Accordingly, all major 
clinical practice guidelines have traditionally accorded 
it an important position in T2DM management. The 
American Diabetes Association/ European 
Association for the Study of Diabetes (ADA/EASD) 
guideline recommends sulfonylureas as first line (if 
metformin is contraindicated or not tolerated), or 
second/third line agent after metformin, if glycaemic 
(30)
target is not attained by monotherapy . Similarly, the 
guidelines and position statements of the International 
Diabetes Federation (IDF), the National Institute for 
Health and Clinical Excellence (NICE), the Scottish 
Intercollegiate Guidelines Network (SIGN), South 
Asian Federation of Endocrine Societies (SAFES), as 
well as national guidelines from Canada, Japan, China 
and South Africa all reflect a generally congruent 
position of sulfonylureas as first or second line agent in 
( 3 1 - 3 8 )
T 2 D M  t r e a t m e n t .  H o w e v e r ,  t h e s e  
recommendations are in conspicuous contrast to the 
latest guidelines of the American College of Physicians 
and the American Association of Clinical  
Endocrinologists (AACE)/ American College of 
(39,40).
Endocrinology (ACE) 
In 2012, the ACP updated its clinical practice guidelines 
on oral pharmacologic management of T2DM, based 
on a systematic evaluation of published evidence (from 
1966 to 2010) comparing efficacy and safety of 
(40)
pharmacologic treatments for T2DM . Among other 
recommendations, the new ACP guideline, like other 
traditional guidelines highlighted above, proposes that 
physicians should prescribe metformin (unless 
contraindicated) as initial pharmacologic therapy 
when lifestyle modification measures fail to adequately 
improve hyperglycaemia. This is on account of its 
extensively proven efficacy, safety and low cost. 
However, if metformin monotherapy fails to 
sufficiently control hyperglycaemia, the ACP guideline 
recommends addition of a second agent, but fails to 
stratify the efficacy of other pharmacologic options to 
guide preference. This, according to the authors, is 
because although some evidence suggests that dual 
therapy regimens containing metformin appear to be 
more effective than any other combination option, or 
monotherapy, there is generally insufficient or unclear 
evidence based on long term outcome measures, to 
recommend one second agent over another. Most long 
term clinical trials compared different levels of 
glycaemic reduction rather than direct head-to-head 
comparison between agents used to attain the 
glycaemic targets, and evidence from newer studies 
with more specific comparison are still considered 
preliminary in terms of long term treatment outcomes 
(41,42)
and clinical event reduction profile . Nevertheless, 
the guideline does state clearly that high-quality 
evidence show that combination therapies containing 
explained by two mechanisms. One mechanism is the 
interaction of sulfonylureaswith certain subtypes of 
sulfonylurea receptors expressed in the heart and 
vessels. Whereas the pancreatic β-cells express SUR1, 
the myocyte and the vascular smooth muscle cell 
express SUR2A and SUR2B. These receptors couple 
with ATP-sensitive K+ channels, and in the presence of 
sulfonylurea, they inhibit cardiac conduction and the 
function of ischemic conditioning, a physiological 
protection of the myocytes against hypoxia. The other 
mechanism of sulfonylurea stems from frequent 
hypoglycaemic episodes, which prolongs QT interval 
(25)
and increases the risk of sudden death .
The third major adverse effect noted in connection with 
sulfonylureas is ablation of pancreatic β-cells. From in 
vitro studies, several sulfonylureas are known to 
induce apoptosis of cultured β-cell lines through 
(26,27)
production of reactive oxygen species . However, 
this relationship is not proven in the clinical settings: a 
continuous decrease in β-cell mass is expected as the 
history of diabetes elongates, and therefore, whether 
sulfonylurea accelerates this trend or not remains 
debatable. On the other hand, GLP-1RA, insulin 
secretagogues that glucose-dependently act and 
imitate the physiological secreting pattern, induce 
proliferation of β-cells in a phosphatidylinositol-
(28)
dependent manner in vitro . Although this probabale 
adverse effect of sulfonylurea is hard to evaluate 
clinically, from a β-cell-preserving point of view, 
precautionary clinical judgement may favour 
significant dose minimization, or possible substitution 
by other antidiabetic agents.
The last major complication is weight gain through 
accumulation of the visceral fat tissue. Insulin is an 
assimilating hormone that promotes storage of glucose 
and synthesis of fatty acids, leading to proliferation of 
the white adipose tissue. The UKPDS and other past 
clinical trials reported weight gain in the patients on 
g l i b e n c l a m i d e  t r e a t m e n t .  F u r t h e r m o r e ,  
adipocytokines secreted from the fat tissue increases 
insulin resistance, which hinders diabetic treatment 
and also raises the risk of dyslipidemia, hypertension, 
or eventually metabolic syndrome. To prevent the 
vicious cycle, a proper diet and a good amount of 
physical exercise are essential to lower the risk of 
(29)
weight gain as much as possible .
Other rarely described adverse effects include: 
c h o l e s t a t i c  j a u n d i c e ,  h a e m o l y t i c a n a e m i a ,  
thrombocytopenia, agranulocytosis; and with 
(20)
chlorpropramide, flushing and hyponatremia .
Current guideline inconsistencies and clinical 
controversy 
As noted earlier, the sulfonylurea is one of the oldest 
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Moreover, while sulfonylureas have the beneficial 
reputation of low cost, the guideline notes that safety 
and efficacy should be given higher priority over initial 
acquisition cost of drugs, since medication cost is only a 
small fraction of the total cost of diabetic care, which 
includes monitoring requirements, risks of 
(39)
hypoglycaemia and weight gain, etc. . In the Cost of 
Type 2 Diabetes in Europe Study, antidiabetic 
medications including insulin accounted for only 
about 7% of healthcare costs, compared to disease and 
management related hospitalizations, which 
(47)
accounted for 55% of total healthcare expenditure . 
Furthermore, while sulfonylureas are known to have 
relatively potent HbA1c lowering effect, they are 
equally known to lack durability. In the ADOPT trial 
which compared the glycaemic durability of the 
sulfonylurea glyburide versus metformin versus 
rosiglitazone monotherapy, glycaemic efficacy in 
terms of reduction in fasting plasma glucose and 
HbA1c levels was greatest with glyburide at 6 months. 
Conversely however, long term glycaemic efficacy was 
worst with glyburide with a five-year treatment failure 
outcome of 34% as against 21% and 15% for metformin 
(48)
and rosiglitazone respectively . A similar observation 
of secondary failure of glycaemic control with 
glibenclamide was also noted in the UKPDS trials. The 
AACE/ACE guideline notes that their lack of 
durability significantly limits the strength of 
recommendation of sulfonylureas.
Although a number of studies and meta-analyses have 
reported a substantially higher risk of mortality and 
cardiovascular complications with sulfonylureas 
(50,51)
compared to other antidiabetic agents , the SAFES 
consensus statement however, argues that many of the 
clinical concerns associated with sulfonylureas are 
agent-specific and should not be generalized for the 
(34)
drug class . Accordingly, it recommends that modern 
sulfonylureas such as gliclazide and glimepiride 
should be preferred over conventional ones such as 
glibenclamide, especially in patients with increased 
risk of hypoglycaemia or cardiovascular disease, or 
those who are overweight or obese. For instance, 
different sulfonylurea agents vary in their 
hypoglycaemic potential, with gliclazide and 
glimepiride showing lower rates of hypoglycaemia 
(52)
compared to glibenclamide . Similarly, a systematic 
review of three randomized control trials concluded 
that gliclazide was associated with the least incidence 
of secondary glycaemic failure from β-cell exhaustion, 
(53)
compared to glibenclamide and glipizide . In 
addition, glimepiride and modified release gliclazide 
have been associated with weight neutrality, at least in 
the first year, and a five-year follow-up of the 
ADVANCE Trial reported similar weight neutrality in 
(54,55)
patients taking regimens containing gliclazide . 
sulfonylureas carry greater risk of adverse effects. It 
noted that the risk of severe hypoglycaemia with 
sulfonylureas significantly exceeds that of metformin 
or TZDs, and that the metformin-sulfonylurea dual 
therapy was associated with six times greater risk of 
hypoglycaemia compared to metformin-TZD 
combination. Although, not explicitly stated in the 
guideline, it is prudent and rational to infer from these 
statements by the ACP that sulfonylureas may not be 
the preferred second line option in pharmacologic 
management of T2DM, and should perhaps be 
considered a third or fourth line option. This inference 
(39)
is consistent with the latest AACE/ACE guidelines . 
The 2016 AACE/ACE Comprehensive Diabetes 
Management Algorithm considers sulfonylureas 
neither as first choice monotherapy option, nor as 
preferred option for dual or triple therapy(39). In fact, 
the algorithm ranks SU lowest among all FDA 
approved classes of medications for T2DM in the 
suggested hierarchy of preference for monotherapy 
(metformin>GLP1-RA>SGLT-2i>DPP4i>AG-I 
>TZD>sulfonylureas/GLN), dual therapy (GLP1-
R A > S G L T - 2 i > D P P 4 i > T Z D > b a s a l  
insulin>colesevelam>bromocriptine QR>AG-I 
>sulfonylureas/GLN) or triple therapy (GLP1-
R A > S G L T - 2 i > T Z D > b a s a l  i n s u l i n > D P P -
4 i > c o l e s e v e l a m > b r o m o c r i p t i n e  Q R > A G - I  
>sulfonylureas/GLN). While the guideline notes that 
all other pharmacologic agents are generally associated 
with fewer adverse events, it warns that sulfonylureas, 
(as well as TZDs and basal insulin) should be used with 
caution as they possess higher adverse event profile 
(hypoglycaemia, weight gain, renal and cardiovascular 
(43)
complications, etc.) . Up to 20% of patients on insulin 
secretagogues experience medication-induced 
hypoglycaemia with sulfonylureas having the highest 
risk of severe hypoglycaemia of any noninsulin 
(44)
therapy . Meanwhile, sulfonylurea-induced severe 
hypoglycaemia is more likely to be protracted with 
greater mortality compared to that induced by 
(45)
insulin . Although sulfonylureas have notable 
glycaemic lowering benefit, it has been shown 
however, that focusing primarily on attaining optimal 
glycaemic limits (HbA1c≤6.5%) increases the risk of 
serious hypoglycaemia without significant reduction 
(46)
in clinical complications . While it considers that 
individual patient context or characteristics and 
medication properties should guide therapeutic agent 
selection, the AACE/ACE guideline emphasizes that 
minimizing the risk of hypoglycaemia and weight gain 
should be a treatment priority as a matter of safety, 
adherence and cost. Accordingly, since sulfonylureas 
are conspicuous culprits of these adverse events, they 
are consequently not considered very favourable 
options. 
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limited in terms of clarifying the various issues noted in 
connection with their clinical application. Even though 
emphasis has recently shifted from group 
characterization to agent-specific judgement of the 
merits and demerits of sulfonylureas, there are still 
insufficient standard trials comprehensively 
evaluating the relative safety and efficacy of different 
sulfonylurea agents. Hence, overall, the current debate 
on the place of sulfonylureas, and the consequent 
clinical dilemma of its use in T2DM management is 
likely to continue, until more scrupulous evidence 
emerge to categorically define its status. Although a 
number of current guidelines do not favour their 
clinical preference, their risk-benefit advantage has yet 
to be completely debunked, and in many regions, they 
are still the most widely prescribed second line agents. 
Meanwhile, over the past two decades, many new oral 
glucose lowering agents with less short term side 
effects have expanded the therapeutic options. 
However, in addition to being comparatively more 
expensive, their long term safety and efficacy 
ramifications are still unknown.
The primary goal of management of T2DM remains to 
reduce the risk of macrovascular and microvascular 
complications, improve quality of life and prolong life 
expectancy of the patients. In meeting this goal, it is 
important to realize that the background medical 
history, the stage of diabetes, and the purpose of 
treatment are all different among the broad spectrum of 
diabetic patients, and that the best treatment strategy 
for each patient would sometimes violate the 
recommendations in guidelines. Accordingly, 
treatment targets such as definition of optimal 
glycemic indices should be individualized and 
dynamic, reflecting each patient's unique and evolving 
clinical circumstances and therapeutic requirements. 
So when considering the appropriate agent for a 
specific patient, many factors such as age, 
comorbidities, stage of disease, drug cost and patient's 
preferences need to be taken into account. Which 
factors would have greater influence in a physician's 
judgment would depend on each country's economic 
status, drug availability and national guidelines for 
T2DM treatment. In view of the clinical issues and 
concerns arising from the current sulfonylurea debate, 
this patient centred approach appears to be the most 
realistic concept for T2DM management in the current 
dispensation, and both physician and patient 
empowerment are imperative in this regard to ensure 
optimal treatment outcome.  
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Gliclazide and glimepiride are also backed by 
favourable data in terms of reduction in all-cause 
mortality and better cardiovascular outcome, 
(25,50)
compared to glibenclamide and glipizide . In the 
light of these specific agent-differences, it may be 
reasonable to suspect that the inconsistencies in 
guidelines in different practice landscapes may to some 
extent reflect the variations in the availability and 
prevalence of use of specific sulfonylurea agents in 
these jurisdictions.
Nevertheless, clinical concerns have heightened 
regarding the status of sulfonylureas in T2DM 
management especially in view of the significant 
discordances in the existing body of relevant literature 
and the latest guidelines. Overall, there is no clear 
consensus in practice, on whether sulfonylureas 
should be used initially, or when it should be added 
subsequent to an initial agent. There is also debate on 
the preference of specific agents within the class in 
different clinical situations, as well as their 
comparative safety, efficacy and pathophysiologic 
effects across different subgroups of T2DM patients, 
such as the newly diagnosed, the long standing 
patients, the obese, the elderly, the pregnant or 
lactating, the paediatric, the co-morbid, etc. It is also 
debatable which management approach is backed by 
superior evidence: a preferred order or algorithm of 
(39)
medications such as proposed by the AACE/ACE , or 
just leaving the decision to the variable interpretations 
and clinical judgements of individual physicians as 
(30)
suggested by the ADA/EASD . Moreover, since most 
of the guidelines focus primarily on drug efficacy and 
safety elements, with less attention on the 
heterogeneous pathogenicity of the disease, the 
complex pathophysiologic basis and dynamic contexts 
of treatment, it is also not clear to what extent this 
limitation impacts on their clinical legitimacy. 
Furthermore, although treatment guidelines are not 
intended in principle to represent a rigid or absolute 
prescriptive template, they are nonetheless generally 
presumed to represent the highest authoritative 
articulation of evidence-informed recommendations of 
best practice. Unfortunately, a recent critical evaluation 
of major practice guidelines on oral antihyperglycemic 
drugs has however, revealed substantial variability in 
the guideline development process and significant 
inconsistencies of recommendations with available 
(57)
evidence , leaving further questions on the technical 
integrity and practical validity of existing guideline 
prescriptions. 
Implications for current practice and perspectives on 
the way forward
While a remarkable body of literature exists on 
sulfonylurea use in T2DM, rigorous evidence is still 
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